Thus, the synergistic activity of this combination approach is likely mediated by driving differential phenotypes and targeting different resistance mechanisms within the same immune cell subset, CD8+ T cells, rather than by targeting the tumor microenvironment and CD8+ T cells, for example. Here, CD8A is linked to neoplasm.